SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion.
Angiotensin-Converting Enzyme 2
Animals
Antibodies, Neutralizing
/ immunology
Antibodies, Viral
/ blood
BNT162 Vaccine
COVID-19
/ immunology
COVID-19 Vaccines
/ immunology
Chlorocebus aethiops
HEK293 Cells
Humans
Immune Evasion
India
Mutation
Protein Binding
SARS-CoV-2
/ genetics
Serine Endopeptidases
Spike Glycoprotein, Coronavirus
/ chemistry
Vero Cells
B.1.617
COVID-19
Indian variant
SARS-CoV-2
antibody escape
evasion
fitness
infectivity
neutralizing antibodies
resistance
spike mutation
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
17 09 2021
17 09 2021
Historique:
received:
12
07
2021
accepted:
13
07
2021
pubmed:
15
7
2021
medline:
30
9
2021
entrez:
14
7
2021
Statut:
ppublish
Résumé
The SARS-CoV-2 B.1.617 variant emerged in the Indian state of Maharashtra in late 2020. There have been fears that 2 key mutations seen in the receptor-binding domain, L452R and E484Q, would have additive effects on evasion of neutralizing antibodies. We report that spike bearing L452R and E484Q confers modestly reduced sensitivity to BNT162b2 mRNA vaccine-elicited antibodies following either first or second dose. The effect is similar in magnitude to the loss of sensitivity conferred by L452R or E484Q alone. These data demonstrate reduced sensitivity to vaccine-elicited neutralizing antibodies by L452R and E484Q but lack of synergistic loss of sensitivity.
Identifiants
pubmed: 34260717
pii: 6321359
doi: 10.1093/infdis/jiab368
pmc: PMC8420622
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
Spike Glycoprotein, Coronavirus
0
ACE2 protein, human
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Serine Endopeptidases
EC 3.4.21.-
TMPRSS2 protein, human
EC 3.4.21.-
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
989-994Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : WT108082AIA
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Science. 2021 Aug 6;373(6555):648-654
pubmed: 34210893
Cell Rep. 2021 Apr 6;35(1):108950
pubmed: 33794145
J Biol Chem. 2020 Sep 11;295(37):13023-13030
pubmed: 32719008
Cell. 2020 Sep 3;182(5):1295-1310.e20
pubmed: 32841599
Mol Biol Evol. 2020 May 1;37(5):1530-1534
pubmed: 32011700
J Virol. 2004 Dec;78(23):13072-81
pubmed: 15542659
Nature. 2020 Dec;588(7839):682-687
pubmed: 33045718
Nature. 2021 Apr;592(7853):277-282
pubmed: 33545711
Nature. 2021 May;593(7857):136-141
pubmed: 33706364
Cell Host Microbe. 2021 Jan 13;29(1):44-57.e9
pubmed: 33259788
Cell Rep Med. 2020 Sep 22;1(6):100099
pubmed: 32905045
Cell. 2020 Aug 20;182(4):828-842.e16
pubmed: 32645326
PLoS One. 2012;7(12):e50859
pubmed: 23227216